The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Overactive Bladder (OAB) Therapeutics Market Research Report 2024

Global Overactive Bladder (OAB) Therapeutics Market Research Report 2024

Publishing Date : Feb, 2024

License Type :
 

Report Code : 1903864

No of Pages : 89

Synopsis
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
The global Overactive Bladder (OAB) Therapeutics market was valued at US$ 5100 million in 2023 and is anticipated to reach US$ 6042.2 million by 2030, witnessing a CAGR of 2.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Overactive Bladder (OAB) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder (OAB) Therapeutics.
Report Scope
The Overactive Bladder (OAB) Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Overactive Bladder (OAB) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Overactive Bladder (OAB) Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Overactive Bladder (OAB) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Overactive Bladder (OAB) Therapeutics Market Overview
1.1 Product Overview and Scope of Overactive Bladder (OAB) Therapeutics
1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.1 Global Overactive Bladder (OAB) Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 Anticholinergic Agents
1.2.3 Beta-3 Adrenoreceptor Agonists
1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3.1 Global Overactive Bladder (OAB) Therapeutics Market Value by Application: (2024-2030)
1.3.2 Hosptial
1.3.3 Clinci
1.3.4 Other
1.4 Global Overactive Bladder (OAB) Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2019-2030
1.4.2 Global Overactive Bladder (OAB) Therapeutics Sales 2019-2030
1.4.3 Global Overactive Bladder (OAB) Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Overactive Bladder (OAB) Therapeutics Market Competition by Manufacturers
2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Overactive Bladder (OAB) Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Product Type & Application
2.7 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends
2.7.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue
2.7.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region
3.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Overactive Bladder (OAB) Therapeutics Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2019-2030
3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2019-2024
3.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2025-2030
3.3 Global Overactive Bladder (OAB) Therapeutics Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2025-2030
3.4 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.4.1 North America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2030)
3.4.3 North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.5.1 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2019-2030)
4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2019-2024)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2025-2030)
4.1.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2019-2030)
5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2019-2024)
5.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2025-2030)
5.1.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 Astellas Pharma
6.2.1 Astellas Pharma Corporation Information
6.2.2 Astellas Pharma Description and Business Overview
6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
6.2.5 Astellas Pharma Recent Developments/Updates
6.3 Hisamitsu Pharmaceutical
6.3.1 Hisamitsu Pharmaceutical Corporation Information
6.3.2 Hisamitsu Pharmaceutical Description and Business Overview
6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.3.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Ferring
6.5.1 Ferring Corporation Information
6.5.2 Ferring Description and Business Overview
6.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
6.5.5 Ferring Recent Developments/Updates
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments/Updates
6.7 Ion Channel Innovations
6.6.1 Ion Channel Innovations Corporation Information
6.6.2 Ion Channel Innovations Description and Business Overview
6.6.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
6.7.5 Ion Channel Innovations Recent Developments/Updates
6.8 Kwang Dong Pharmaceutical
6.8.1 Kwang Dong Pharmaceutical Corporation Information
6.8.2 Kwang Dong Pharmaceutical Description and Business Overview
6.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.8.5 Kwang Dong Pharmaceutical Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products
6.9.1 Lanzhou Institute of Biological Products Corporation Information
6.9.2 Lanzhou Institute of Biological Products Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 ONO Pharmaceutical
6.11.1 ONO Pharmaceutical Corporation Information
6.11.2 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.11.5 ONO Pharmaceutical Recent Developments/Updates
6.12 Sanofi
6.12.1 Sanofi Corporation Information
6.12.2 Sanofi Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
6.12.5 Sanofi Recent Developments/Updates
6.13 Tengion
6.13.1 Tengion Corporation Information
6.13.2 Tengion Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
6.13.5 Tengion Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis
7.2 Overactive Bladder (OAB) Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Overactive Bladder (OAB) Therapeutics Production Mode & Process
7.4 Overactive Bladder (OAB) Therapeutics Sales and Marketing
7.4.1 Overactive Bladder (OAB) Therapeutics Sales Channels
7.4.2 Overactive Bladder (OAB) Therapeutics Distributors
7.5 Overactive Bladder (OAB) Therapeutics Customers
8 Overactive Bladder (OAB) Therapeutics Market Dynamics
8.1 Overactive Bladder (OAB) Therapeutics Industry Trends
8.2 Overactive Bladder (OAB) Therapeutics Market Drivers
8.3 Overactive Bladder (OAB) Therapeutics Market Challenges
8.4 Overactive Bladder (OAB) Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’